Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of TNO155 in Hepatic Impairment
NCT05490030Phase 1Withdrawn
- Sponsor
- Novartis
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of batoprotafib in solid tumor (4 arms), sponsored by Novartis. Primary endpoints: Area under the plasma concentration-time curve from time zero to the last measurable concentration, Area under the plasma concentration-time curve from time zero to time t and 6 more. Planned start Mar 2025; status: withdrawn.
02
Drugs
batoprotafib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05490030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05490030.